Table 3.
Univariate analysis (categorical variables)
| Variables | pCR | No pCR | X2 | Significance (p value - 2 tailed) |
|---|---|---|---|---|
| Morphology (n = 240)) | ||||
| IDC | 55 | 176 | 0.85 | 0.65 |
| ILC | 1 | 7 | ||
| Others | 0 | 1 | ||
| Grade (n = 237) | ||||
| Low grade(G1 + G2) | 18 | 90 | 4.22 | 0.04 |
| High grade(G3) | 36 | 93 | ||
| Pre chemo clinical nodal status (n = 234) | ||||
| Involved | 44 | 158 | 1.39 | 0.23 |
| Uninvolved | 10 | 22 | ||
| Skin Involvement by tumor (n = 240) | ||||
| Involved | 28 | 93 | 0.005 | 0.94 |
| Uninvolved | 28 | 91 | ||
| Estrogen Receptor (n = 239) | ||||
| Positive | 37 | 133 | 0.911 | 0.3 |
| Negative | 19 | 50 | ||
| Progesterone Receptor (n = 239) | ||||
| Positive | 20 | 108 | 9.36 | 0.002 |
| Negative | 36 | 75 | ||
| Her2 Receptor (n = 238) | ||||
| Positive | 22 | 71 | 0.252 | 0.98 |
| Negative | 27 | 93 | ||
| Equivocal | 6 | 19 | ||
| Luminal Classification (n = 233) | ||||
| Triple negative | 10 | 23 | 1.16 | 0.57 |
| HER2 enriched | 6 | 19 | ||
| Luminal type | 38 | 137 | ||
| Trastuzumab (n = 93) | ||||
| Taken | 10 | 13 | 6.648 | 0.01 |
| Not taken | 12 | 58 | ||
| Type of Chemotherapy (n = 237) | ||||
| Anthracycline followed by Taxane | 50 | 163 | .084 | 0.77 |
| Anthracyclin or Taxane | 5 | 19 | ||